http://eyewiretoday.com/ Newest Articles en-us Wed, 10 Mar 2010 23:04:29 GMT Wed, 10 Mar 2010 23:04:29 GMT Eyetube.net http://eyewiretoday.com/view.asp?url=20100310-professor_discovers_link_that_could_help_treatments_for_retinoblastoma What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma. Dolores Takemoto, a Kansas State University professor of biochemistry who wa... Wed, 10 Mar 2010 13:52:00 GMT http://eyewiretoday.com/view.asp?url=20100310-bioness_to_distribute_new_products_for_neurologically_impaired_patients VALENCIA, Calif. -- Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech, LLC, Bio... Wed, 10 Mar 2010 13:50:00 GMT http://eyewiretoday.com/view.asp?url=20100310-carb_intake_tied_to_cataract_risk MELBOURNE, AustraliaWomen who consume higher amounts of carbohydrates appear to have a greater risk of developing cortical and nuclear lens opacities, according to new findings from the Melbourne Visual Impairment Project (Invest Ophthalmol Vis Sci. ... Wed, 10 Mar 2010 13:45:00 GMT http://eyewiretoday.com/view.asp?url=20100310-novartis_announces_5_billion_bond_issue_to_fund_alcon_purchase BASEL, Switzerland - Swiss drug maker Novartis AG announced Wednesday a $5 billion bond issue to finance its purchase of eye-care company Alcon Inc. The pharmaceuticals company said the notes will be issued in three parts by its U.S. subsidiary Novar... Wed, 10 Mar 2010 13:43:00 GMT http://eyewiretoday.com/view.asp?url=20100310-santen_announces_change_in_management_structure Osaka, Japan Santen Pharmaceutical Co., Ltd., Japan's leading ophthalmic pharmaceutical company, announced today that Adrienne L. Graves, PhD, President and Chief Executive Officer of its wholly-owned U.S. subsidiary, Santen Inc. (Napa, CA), has res... Wed, 10 Mar 2010 13:40:00 GMT http://eyewiretoday.com/view.asp?url=20100310-anti-amd_drug_use_stirs_concern_in_canada Intravitreal drug injections for age-related macular degeneration have mushroomed in at least one Canadian province in recent years, likely adding fuel to a controversy over off-label use of bevacizumab (Avastin) for this purpose. Medical records in ... Wed, 10 Mar 2010 13:33:00 GMT http://eyewiretoday.com/view.asp?url=20100310-canadian_research_links_anti-depressants_cataracts Some depression and anxiety drugs are associated with an increased risk of cataracts, new research shows. According to the study in the journal Ophthalmology, British Columbia and Quebec researchers found a link between cataracts and some drugs in a ... Wed, 10 Mar 2010 13:30:00 GMT http://eyewiretoday.com/view.asp?url=20100310-humana_expands_vision_insurance_to_new_states The controversy over health insurance reform has led to a backlash against many health insurance providers who have begun raising premiums and individual plans in anticipation of the coming overhaul. Among these groups is Humana Inc., which has just ... Wed, 10 Mar 2010 13:27:00 GMT http://eyewiretoday.com/view.asp?url=20100309-scientists_shed_new_light_on_how_retinas_hardware_is_used_in_color_vision Biologists at New York University and the University of Wrzburg have identified, in greater detail, how the retina's cellular hardware is used in color preference. The findings, published in the latest issue of the Proceedings of the National Academy... Tue, 9 Mar 2010 13:37:00 GMT http://eyewiretoday.com/view.asp?url=20100309-ista_says_fda_to_review_eye_drug_by_oct_16 ISTA Pharmaceuticals Inc. said Monday the Food and Drug Administration will make a regulatory decision on the once-daily eye inflammation treatment XiDay by Oct. 16. The drug is a once-per-day version of Xibrom, a drug that is already on the market b... Tue, 9 Mar 2010 13:29:00 GMT http://eyewiretoday.com/view.asp?url=20100309-cataract_risk_increases_with_anti-depressants Researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University have found that some anti-depressant drugs are associated with an increased risk of developing cataracts. The study, based on a datab... Tue, 9 Mar 2010 13:27:00 GMT http://eyewiretoday.com/view.asp?url=20100309-high_eye_pressure_monitor_or_treat? Most people at risk for developing glaucoma due to high eye pressure do not need treatment, according to a large, multi-center study. The Ocular Hypertension Treatment Study (OHTS) investigators, led by researchers at Washington University School of ... Tue, 9 Mar 2010 13:23:00 GMT http://eyewiretoday.com/view.asp?url=20100309-treatment_of_retinal_disease_more_frequently_involves_eye_injections Use of medications injected directly into the eye appears to be an increasingly common treatment for age-related macular degeneration in one region of Canada, but only a small proportion of ophthalmologists perform the procedure, according to a repor... Tue, 9 Mar 2010 13:20:00 GMT http://eyewiretoday.com/view.asp?url=20100309-waiting_safe_for_some_at_risk_of_glaucoma Eye doctors can often treat glaucoma successfully if they catch it early, but a new study suggests that ophthalmologists can sometimes wait before treating those at risk of developing the disease. If their ophthalmologists choose to postpone treatmen... Tue, 9 Mar 2010 13:19:00 GMT http://eyewiretoday.com/view.asp?url=20100309-allergan_ceo_got_111m_in_compensation_in_2009 The CEO of Botox maker Allergan Inc. received compensation valued at $11.1 million in 2009, according to an Associated Press calculation of figures filed with regulators. That was a drop of 18 percent from 2008. Chairman and CEO David Pyott's salary ... Tue, 9 Mar 2010 13:17:00 GMT http://eyewiretoday.com/view.asp?url=20100308-ama_to_help_docs_cash_in_on_ehr_stimulus_dollars Doctors that demonstrate the "meaningful use" of electronic health records (EHR) in their practices are eligible for at least $44,000 over five years, an incentive the American Medical Association (AMA) is facilitating with a new partnership. AMA's p... Mon, 8 Mar 2010 13:42:00 GMT http://eyewiretoday.com/view.asp?url=20100308-fera_pharmaceuticals_now_shipping_erythromycin_ophthalmic_ointment Erythromycin ophthalmic ointment is now available after a previous market shortage, manufacturer Fera Pharmaceuticals (New York) said in a press release. Last summer the company acquired erythromycin and six other ophthalmic ointments; during the tra... Mon, 8 Mar 2010 13:38:00 GMT http://eyewiretoday.com/view.asp?url=20100308-why_our_peripheral_vision_may_not_be_as_random_as_we_think As you read this, you may notice that the word directly in front of youis clear, but all the surrounding words are hard to make out. For mostpeople, this effect - known as 'crowding' - is not a problem. However,for the millions of people worldwide wh... Mon, 8 Mar 2010 13:29:00 GMT http://eyewiretoday.com/view.asp?url=20100308-final_health_care_reform_votes_loom WASHINGTON -- President Barack Obama unveiled his healthcare plan this week and laid out an ambitious time line that would have Congress passing a final healthcare bill within two weeks. Obama announced his plan at the White House on Wednesday, ackno... Mon, 8 Mar 2010 13:26:00 GMT http://eyewiretoday.com/view.asp?url=20100305-positive_24-month_data_from_iluvien_phase_3_fame_study_for_dme_at_angiogenesis pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, said that 24-month data from the FAME Phase 3 s... Fri, 5 Mar 2010 13:42:00 GMT http://eyewiretoday.com/view.asp?url=20100305-nicox_2009_announces_full_year_2009_financial_results NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2009 and provided an overview of its activities, in particular those related to its lead compound naproxcinod, which is currently under review by the US Food an... Fri, 5 Mar 2010 13:28:00 GMT http://eyewiretoday.com/view.asp?url=20100305-surmodics_announces_organizational_and_leadership_changes SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today certain organizational and leadership changes designed to support future growth by better meeting customer needs, l... Fri, 5 Mar 2010 13:26:00 GMT http://eyewiretoday.com/view.asp?url=20100305-inspire_reports_full_year_2009_financial_results Full Year Revenue Increased 31% and Net Loss Decreased 23%. Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fou... Fri, 5 Mar 2010 13:24:00 GMT http://eyewiretoday.com/view.asp?url=20100305-amos_mazzo_named_chairman_of_advameds_board_of_directors The Advanced Medical Technology Association (AdvaMed) today announced that Abbott Medical Optics President James V. Mazzo starts a two-year term as Chairman of the AdvaMed Board of Directors. Mazzo succeeds Edwards Lifesciences Chairman and CEO Micha... Fri, 5 Mar 2010 13:20:00 GMT http://eyewiretoday.com/view.asp?url=20100304-oxford_biomedica_acquires_intellectual_property_rights_for_gene-based_ocular_products Oxford BioMedica UK Ltd. (Oxford, U.K.) has entered into a license agreement with the Research Development Foundation, the technology transfer arm of the Clayton Foundation for Research (Houston), the company said in a press release. The terms of the... Thu, 4 Mar 2010 13:48:00 GMT